Blue Tip Micro Hematocrit Capillary Tube

Name: Blue Tip Micro Hematocrit Capillary Tube
Brand: Jiangsu Junyue Medical Science and Technology Co., Ltd.
SKU: 2119592545

Jiangsu, ChinaJiangsu Junyue Medical Science and Technology Co., Ltd.

US$0.30-0.50

5,000 barrel

Sample price:US$1.00/piece.Request sample

Product profile

Customization

Available

Type

Test Strips & Test Tube

Ethylene Oxide Sterilization

Model NO.

CP001

Logo Printing

With Logo Printing

Model No.

Cp001

Product Name

Capillary Tube

Volume

70UL

Additive

No Additive/Lithium Heparin

Intend Use

Blood Collection

Certificate

CE, ISO

OEM/ODM

Available

Sample

Free Sample, Freight Collected

Transport Package

100pcsx500barrels

Specification

70ul

Trademark

JUNYUEMED

Origin

China

Production Capacity

20000barrels/Day

Company profile

Fast DeliveryQuality AssuranceManagement CertificationEnvironmental Protection

Jiangsu Junyue Medical Science and Technology Co., Ltd.

Jiangsu, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service Available CertifiedCustomization Options: Customization from Samples, Customization from Designs, etc. CertifiedExport Year: 3 Years CertifiedNearest Port: Shanghai PortAverage Response Time: >24h

AI-Powered supplier vetting

SummaryJiangsu Junyue Medical Technology Co., Ltd. is identified as a combined company involved in medical-device production and related plastic and glass-instrument activities. It demonstrates 3D design, ODM, OEM, customization, patented technology, independent intellectual property, and recent new-product activity. Quality procedures include documented corrective actions, complaint handling, quality assurance, and finished-product inspection instructions. The supplier has inventory capability and export experience, but lacks an effective manufacturing contract with related subcontractors, overseas warehouses, overseas showrooms, overseas agents or branches, and offline trade-show participation. Financial credibility cannot be assessed from the provided information because the relevant entry gives only a year rather than financial performance or capacity evidence. Customer-case evidence is limited: OEM service for well-known brands is stated, but no Fortune 500 collaboration is reported.

Supplier typeThe supplier is classified as a combined company and is authorized for specified medical-device production and business activities. Its stated scope also includes plastic products, glass instruments, technology transfer, and import/export activities, indicating a diversified manufacturing and technology-oriented profile.

After-Sales capabilityThe supplier has documented procedures and records for corrective and preventive actions and customer complaints, supporting a structured service-response process. However, it has no overseas agents or branches, no overseas warehouse, and no overseas showroom, which limits demonstrated overseas service infrastructure.

R&D capabilityThe supplier provides 3D software design, ODM, and multiple forms of customization; it reports new products in the past year, two R&D engineers, patented technologies, and independent intellectual property rights. It lacks an available SDK, but the documented product-development and IP activity supports innovation capability overall.

Production capacityThe supplier reports medical-device production authorization, plastic-product and glass-instrument manufacturing activities, and in-stock capability. Nevertheless, it explicitly lacks a valid contract with related subcontractors, creating a documented weakness in manufacturing-capacity governance.

Customization capabilityThe supplier explicitly offers customization from samples, customization from designs, full customization, minor customization, flexible customization, 3D software design, and ODM services. These statements directly demonstrate broad customization capability.

Client casesThe supplier states that it provides OEM services for well-known brands, which is direct evidence of relevant customer experience. However, it reports no collaboration with Fortune 500 companies, so the available customer-case evidence is positive but limited in scale and detail.